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Regulatory guidelines describe the use of estimands in designing and conducting clini-
cal trials. Estimands ensure alignment of the objectives with the design, conduct and
analysis of a trial. An estimand is defined by four inter-related attributes: the population
of interest, the variable (endpoint) of interest, the way intercurrent events are handled
and the population level summary. A trial may employ multiple estimands to evaluate
treatment effects from different perspectives in order to address different scientific
questions. As estimands may be an unfamiliar concept for many clinicians treating dia-
betes, this paper reviews the estimand concept and uses the PIONEER 1 phase 3a clin-
ical trial, which investigated the efficacy and safety of oral semaglutide vs placebo, as
an example of the way in which estimands can be implemented and interpreted. In the
PIONEER 1 trial, two estimands were employed for each efficacy endpoint and were
labelled as: (a) the treatment policy estimand, used to assess the treatment effect
regardless of use of rescue medication or discontinuation of trial product, and provides
a broad perspective of the treatment effect in the population of patients with type
2 diabetes in clinical practice; and (b) the trial product estimand, used to assess the
treatment effect if all patients had continued to use trial product for the planned dura-
tion of the trial without rescue medication, thereby providing information on the antici-
pated treatment effect of the medication. Both approaches are complementary to
understanding the effect of the studied treatments.
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1 | INTRODUCTION
A key objective of many randomized clinical trials is quantification of
the treatment effect of an intervention, such as a device or medication,
compared with a control such as placebo or an active treatment, to*Joint first authors.
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inform clinical and regulatory decision making. Various types of treat-
ment effects can be defined, and different stakeholders may have con-
flicting views on the relevance and applicability of the treatment
effects described. Whenever results from clinical trials are published, it
is crucial to accompany the results with a precise explanation of the
way in which data that may have been impacted by intercurrent events,
such as use of rescue medication or trial product discontinuation, are
accounted for, and thus the way in which treatment effects have been
estimated.
In 2008, the US Food and Drug Administration (FDA) issued a
draft guideline that recommended the use of a last-observation car-
ried forward (LOCF) approach, in which missing data are replaced with
the last observed value for a patient who discontinued the trial or
treatment.1 The LOCF approach implicitly assumes that a patient with
good short-term disease control who prematurely discontinues the
trial or trial product would also have similarly good disease control in
the longer term.2 As this assumption is debatable in many settings,
and because the LOCF approach may result in bias in favour of the
tested therapy,3 a 2010 National Research Council (NRC) report,
commissioned by the FDA, subsequently recommended against use of
LOCF as a primary approach to handle missing data unless scientifi-
cally justified.2 Other methods to handle missing data have since been
adopted, including multiple imputation approaches and the mixed
model for repeated measures (MMRM), which are employed
according to the type of treatment effect to be estimated.4
In the past, the type of treatment effect to be estimated was often
insufficiently described in trial protocols or publications, which could
have led to ambiguity and difficulties in interpreting data or comparing
results from other trials. Because of a need for greater clarity and
transparency, the International Council for Harmonisation (ICH)
Steering Committee endorsed the ICH E9 (R1) concept paper in 2014
concerning this topic5 and a draft addendum was made available for
public consultation in 20176 by various regulatory agencies, including
the European Medicines Agency (EMA)7 and the FDA.8 This draft
addendum presents a “structured framework to link trial objectives to
a suitable trial design and tools for estimation and hypothesis testing
and introduces the concept of an estimand, translating the trial objec-
tive into a precise definition of the treatment effect that is to be esti-
mated.”6 The estimand concept is not new but, until recently,
estimands have not been explicitly defined in clinical trial protocols or
in publications.
The PIONEER programme is a global, clinical development pro-
gramme for a novel oral formulation of the glucagon-like peptide-1
(GLP-1) analog, semaglutide. Trials in the PIONEER programme,
including PIONEER 19 and PIONEER 3,10 are some of the first clinical
trials in type 2 diabetes to introduce estimands into trial planning, trial
conduct, data analysis and interpretation of results. The decision to
adopt the estimand concept in the PIONEER programme was made
after the concept paper1 was released and following interactions with
regulatory authorities, but before the draft ICH E9 addendum6 was
available for public consultation. In this review, we will discuss
estimands and their incorporation in the PIONEER development pro-
gramme. The PIONEER 1 trial will be used as an example, to provide
an understanding of the estimands implemented in the PIONEER pro-
gramme and to clarify the considerations for clinical interpretation.
Although future trials may involve different scientific questions and,
consequently, may use different estimands than those used in the
PIONEER 1 trial, an understanding of the estimand concept will help
readers in designing and interpreting future trials.
2 | THE ESTIMAND CONCEPT: DEFINING
THE TARGET OF ESTIMATION
An estimand is a detailed description of the type of treatment effect
that is to be estimated in order to address the scientific question of
interest. It is important to emphasize that “estimand” is not a statisti-
cal term. Together with the structured framework, rigorous definition
of the estimands used provides transparency and alignment of the
trial objective, design, conduct and analysis, and thereby ensures that
the planned treatment effect is actually the treatment effect that is
eventually estimated. In a clinical trial, more than one estimand can be
included for the same endpoint in the protocol.
An estimand is defined by four inter-related attributes:
i. population of interest, that is, the population targeted by the sci-
entific question of interest, for example, adult patients with type
2 diabetes;
ii. variable (endpoint) of interest, for example, change from baseline
in glycated haemoglobin (HbA1c) at Week 26;
iii. the way to handle intercurrent events, for example, the way to
account for use of rescue medication or premature trial product
discontinuation in addressing the scientific question of interest;
iv. population level summary, for example, the mean difference
between treatment groups.
Previously, attributes i, ii and iv were clearly defined in clinical trial
protocols. However, attribute iii, intercurrent events, described as
“Events that occur after treatment initiation and either preclude
observation of the variable or affect its interpretation,”6 was often not
explicitly defined. Rather, intercurrent events were defined implicitly
by specification of the statistical analyses.11 Thus, the choices for col-
lection of data and the statistical analyses indicated the scientific
question of interest rather than using the scientific question to guide
decisions concerning data collection and statistical analyses. The ICH
E9 (R1) draft addendum emphasizes the importance of utilizing the
framework in a sequential manner, such that the estimand determines
the method of estimation, that is, the analysis.6
Intercurrent events may “include the use of an alternative treat-
ment (e.g., a rescue medication, a medication prohibited by the proto-
col or a subsequent line of therapy), discontinuation of treatment,
treatment switching and terminal events, […] such as death.”6 For
example, during a diabetes trial, patients may be allowed to receive
another glucose-lowering agent as rescue medication if they do not
maintain acceptable glycaemic control during the course of the trial;
however, the use of rescue medication may alter the treatment effect
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that is ultimately assessed. Considering change in HbA1c as the end-
point in a placebo-controlled design, the use of rescue medication will
probably occur more commonly in participants receiving placebo than
in those receiving an active trial product. If measurements collected
after initiation of rescue medication contribute to the estimated treat-
ment effect, this would lead to a smaller estimated difference in
HbA1c between treatment arms. Hence, the estimated treatment
effect reflects a comparison of the effect of the active trial product
plus the potential effect of rescue medication vs the effect of placebo
plus the potential effect of rescue medication. The relevance of such
a treatment effect depends on the scientific question posed.
Another common intercurrent event in diabetes trials is premature
discontinuation of trial product, for example, due to adverse events.
The relevance of including measurements collected after trial product
discontinuation, again, depends on the question of interest. If the ques-
tion of interest is to estimate the effect of the trial product in a scenario
in which patients had continued to use trial product and did not use res-
cue medication, HbA1c measurements after a patient discontinued trial
product are not relevant. However, if it is of interest to compare treat-
ment policies, and to take into account both efficacy and tolerability,
measurements after having discontinued trial product are relevant, as
discontinuations may occur because of adverse events.
Different strategies can be used to account for intercurrent
events, to construct an estimand that allows assessment of the treat-
ment effect specified by the scientific question of interest. Five strate-
gies are discussed in draft ICH E9 (R1). In brief: (a) the “treatment
policy strategy", in which measurements of the variable of interest are
used regardless of the occurrence of the intercurrent event; (b) the
“hypothetical strategy", which envisages a scenario in which an inter-
current event, such as use of rescue medication or discontinuation of
medication, would not have occurred; (c) the “composite strategy", in
which an intercurrent event may be integrated into one or more other
measures of a clinical outcome as the variable of interest; (d) the “prin-
cipal stratum strategy", in which the target population might be taken
as a subset of the broader population in which the intercurrent event
would not occur; and (e) the “while-on-treatment strategy", in which
the treatment effect achieved before occurrence of the intercurrent
event is of interest. In addition to the five strategies discussed in the
draft ICH E9 (R1) guideline, others may be relevant.6
The choice of estimand for a clinical trial, and the subsequent ana-
lyses to be performed, should be made with the scientific question of
interest in mind. For example, it may be of interest to understand the
treatment effect in patients if they had continued to use treatment
for the duration of the trial, without rescue medication. Alternatively,
it may be of interest to understand the overall treatment effect, taking
into consideration tolerability and/or efficacy issues that may result in
medication discontinuation or additional therapy. There are many dif-
ferent scientific questions of interest relevant to clinical trials and,
therefore, different ways in which estimands can be utilized to
address these questions.12-17
The ICH E9 (R1) presents a general framework along with the
estimand concept and does not recommend the use of specific
estimands, as the relevance of an estimand depends on the clinical
setting and scientific question of interest. In early 2018, the EMA pub-
lished a draft guideline18 that specifically discusses the use of
estimands in diabetes trials. The draft guideline recommends that the
primary estimand for glycated haemoglobin should utilize the hypo-
thetical strategy to account for the intercurrent event,“initiation of
rescue medication” and to use the treatment policy strategy for the
intercurrent event, “trial product discontinuation.” Hence, a treatment
effect that is free from the impact of other glucose-lowering agents,
regardless of trial product discontinuation, is targeted. A supplemen-
tary suggestion in the EMA draft guideline is to use the composite
strategy to account for the two intercurrent events through definition
of the endpoint: the difference in proportion of patients who reached
an absolute HbA1c value of <7.0% (<53 mmol/mol) at end-of-trial
without the use of additional medication and who continued to use
trial product for the duration of the trial.
It is important when planning a new trial to consider all relevant
intercurrent events and to be able to justify the strategy chosen to
account for these. For example, the treatment policy strategy, in
which a treatment effect is assessed regardless of intercurrent events,
will often tend to minimize the difference in treatment effect between
groups. It should also be taken into consideration whether it is justifi-
able to account for the intercurrent event of premature trial product
discontinuation because of drug-related adverse events according to
the hypothetical strategy, in which the estimated treatment effect
assumes that patients continued using trial drug even if not tolerated.
A clear, precise description of the type of treatment effect
(estimand) to be estimated in the trial will make it easier for clinical
trialists, physicians and other stakeholders to understand and interpret
results from clinical trials. Clinical trial sponsors are responsible for
choosing and defining the estimands that best answer the questions
of interest according to the disease and the population, and for work-
ing with decision makers and clinical stakeholders to ensure that the
estimand(s) applied is(are) appropriate. A collaborative approach
across different areas of expertise is required when defining
estimands.
3 | HOW ESTIMANDS WERE
INCORPORATED INTO THE PIONEER 1 TRIAL
PIONEER 1 was a phase 3a, randomized, placebo-controlled trial com-
paring once-daily oral semaglutide 3, 7 and 14 mg with placebo in
adult patients with type 2 diabetes who, at trial entry, were being
treated only with advice concerning diet and exercise
(NCT02906930).9 This trial, as others in the PIONEER programme (eg,
PIONEER 3),10 employed two estimands, labelled “treatment policy
estimand” and “trial product estimand,” to address two different scien-
tific questions of interest and to provide information relevant to regu-
latory agencies and/or clinicians concerning oral semaglutide. The trial
was designed to evaluate adult patients with type 2 diabetes who
would be eligible for oral semaglutide in clinical practice, and to assess
variables of interest relevant to a GLP-1 analog (eg, HbA1c and body
weight). For both estimands employed in the PIONEER programme,
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two intercurrent events were considered: initiation of rescue medica-
tion and premature trial product discontinuation. These events were
handled differently according to the scientific question of interest
(Figure 1).
The treatment policy estimand aimed to answer the question:
What is the treatment effect in the targeted population of patients
with type 2 diabetes regardless of trial product discontinuation or use
of rescue medication? The treatment policy estimand for the efficacy
objectives in the PIONEER 1 trial was the primary estimand, and was
defined as the mean difference between oral semaglutide and placebo
in change from baseline to Week 26 in HbA1c and body weight in
patients with type 2 diabetes, regardless of trial product discontinua-
tion and/or addition of rescue medication or switch to another
glucose-lowering drug. It is noteworthy that, in the PIONEER 1 trial,
rescue medication was recommended for participants with persistent
and unacceptable hyperglycaemia, that is, confirmed fasting blood
F IGURE 1 Illustration of
estimands used in the PIONEER 1 trial.
HbA1c, glycated haemoglobin
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glucose greater than 240 mg/dL (13.3 mmol/L) during Weeks 8 to
13, or greater than 200 mg/dL (11.1 mmol/L) fromWeek 14 onwards.9
The two anticipated intercurrent events were both accounted for by
the treatment policy strategy as described in the draft ICH E9
(R1) addendum.6 One implication for trial design and conduct when
applying this estimand was that all patients were encouraged to con-
tinue participation in the trial and data were collected even after dis-
continuation of trial product. This contrasts with historical approaches
in which data would not have been collected following trial product
discontinuation.2 This estimand may, therefore, be of interest to both
regulatory authorities and clinicians.
The trial product estimand aimed to answer the question: What is
the treatment effect in the targeted population of patients with type
2 diabetes if all patients had continued to use trial product and did
not use rescue medication? and this was the secondary estimand in








Analysis of covariance. Missing values were imputed 
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ETD [95%CI]: %; mmol/mol; P value
Oral semaglutide 3 mg vs placebo:
     –0.6 [–0.8 to –0.4]%; –6 [–9 to –4] mmol/mol; P<0.001
Oral semaglutide 7 mg vs placebo:
     –0.9 [–1.1 to –0.6]%; –9 [–12 to –7] mmol/mol; P<0.001
Oral semaglutide 14 mg vs placebo:











































ETD [95%CI]: %; mmol/mol; P value
Oral semaglutide 3 mg vs placebo:
     –0.7 [–0.9 to –0.5]%; –7 [–10 to –5] mmol/mol; P<0.001
Oral semaglutide 7 mg vs placebo:
     –1.2 [–1.5 to –1.0]%; –14 [–16 to –11] mmol/mol; P<0.001
Oral semaglutide 14 mg vs placebo:





































ETD [95%CI]: kg; P value
Oral semaglutide 3 mg vs placebo:    –0.1 [–0.9 to 0.8] kg; P=0.87
Oral semaglutide 7 mg vs placebo:    –0.9 [–1.9 to 0.1] kg; P=0.09









































ETD [95%CI]: kg; P value
Oral semaglutide 3 mg vs placebo:    –0.2 [–1.0 to 0.6] kg; P=0.71
Oral semaglutide 7 mg vs placebo:    –1.0 [–1.8 to –0.2] kg; P=0.01


































F IGURE 2 Estimand description and results from the PIONEER 1 trial. Change from baseline in A, HbA1c and B, body weight for the
treatment policy estimand and the trial product estimand at Week 26.9 ETDs [95% CI] are shown. American Diabetes Association PIONEER 1:
Randomized Clinical Trial Comparing the Efficacy and Safety of Oral Semaglutide Monotherapy with Placebo in Patients with Type 2 Diabetes,
American Diabetes Association, 2019. Copyright and all rights reserved. Material from this publication has been used with the permission of
American Diabetes Association. CI, confidence interval; ETD, estimated treatment difference; HbA1c, glycated haemoglobin. aRescue medication
criteria: confirmed fasting blood glucose greater than 240 mg/dL (13.3 mmol/L) from week 8 to 13, or greater than 200 mg/dL (11.1 mmol/L)
from week 14 onwards. bIn PIONEER 1, trial product discontinuation rates were 2.3% to 7.4% with oral semaglutide and 2.2% with placebo
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mean difference between oral semaglutide and placebo in change
from baseline to Week 26 in HbA1c and body weight in patients with
type 2 diabetes if all patients had continued to use trial product for
the entire planned duration of the trial and did not use rescue medica-
tion. Thus, both intercurrent events were accounted for by the hypo-
thetical strategy as described in the draft ICH E9 (R1).6 The trial
product estimand aims at targeting the effect if patients had contin-
ued to use treatment with oral semaglutide, compared with the effect
if patients had continued to use placebo, without the confounding
effects of rescue medication or any other changes in glucose-lowering
medication. The trial product estimand adds clinical value by aiming to
provide information concerning the anticipated effect of trial product.
4 | STATISTICAL METHODS USED IN THE
PIONEER 1 TRIAL
In the PIONEER 1 trial, confirmation of the efficacy of oral semaglutide
on change in HbA1c and in body weight from baseline to Week
26 was based on a weighted Bonferroni closed-testing strategy, to
control the overall type 1 error for the hypotheses evaluated by the
treatment policy estimand.9 The statistical analysis should be aligned to
estimands of interest6 and the following pre-specified analyses were
used to estimate each of the estimands in the PIONEER 1 trial.
The treatment policy estimand was estimated by a pattern mixture
model, using multiple imputation to handle missing data from Week
26 for both confirmatory endpoints (Figures 1 and 2). Data collected
at Week 26 from all randomized patients, irrespective of premature
discontinuation of trial product and/or initiation of rescue medication,
were included in the statistical analysis. Imputation was undertaken
within groups, defined by trial product and treatment status at Week
26. The assumption is that the behaviour of patients who discon-
tinued trial product or initiated rescue medication, but for whom data
were missing at the primary evaluation time point, is best described
by patients with the same treatment status for whom data were avail-
able at the primary evaluation time point. The treatment policy
estimand used in the PIONEER 1 trial may provide a broad perspec-
tive of the treatment effect and the statistical approach relies on
fewer assumptions than other statistical approaches.6 Both
imputation and analysis were based on analysis of covariance models.
Results were combined by use of Rubin's rule.19 Recent US prescrib-
ing information for the subcutaneous GLP-1 receptor agonist
semaglutide20 reported results with an approach similar to that used
in the PIONEER 1 trial to estimate the treatment policy estimand.
The trial product estimand was estimated using an MMRM that
incorporated data from all randomized patients, collected prior to pre-
mature trial product discontinuation or initiation of rescue medication
(Figures 1 and 2). The independent effects included in the model were
treatment and region as categorical fixed effects and baseline value as
a covariate, all nested within visit. An unstructured covariance matrix
for endpoint measurements within the same patient was employed.9
The MMRM is based on the assumption that data are missing at ran-
dom, meaning that patients for whom data were missing would be
considered to behave similarly to other patients in the same treatment
group. The trial product estimand aims to provide information con-
cerning the anticipated effect of trial product, but should not be con-
sidered equivalent to the per-protocol or complete case analysis. The
MMRM analysis used to estimate the trial product estimand differs
from a per-protocol or complete-case analysis because it includes data
from all randomized patients, rather than a subset of the randomized
patients. Recent EU prescribing information for the subcutaneous
GLP-1 receptor agonist semaglutide21 reported results with an
approach similar to that used in the PIONEER 1 trial to estimate the
trial product estimand.
5 | INTERPRETING RESULTS FROM
ESTIMANDS INCORPORATED INTO THE
PIONEER 1 TRIAL
In the PIONEER 1 trial, all dose levels of oral semaglutide were superior
to placebo in reducing HbA1c and superior reductions in body weight
were observed for the 14 mg dose compared with placebo (Figure 2).
In the PIONEER 3 trial, compared with sitagliptin, the 7 mg and 14 mg
doses of oral semaglutide resulted in superior reductions in HbA1c and
body weight.10 While the two estimands used in the PIONEER 1 and
PIONEER 3 trials addressed two different scientific questions of inter-
est, both contribute to the full clinical picture. As outlined earlier, the
Time since randomization (weeks)
On-treatment without rescue medication
Premature trial product discontinuation
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On-treatment with rescue medication
Withdrawn
The bands represent the proportion of subjects by treatment status until the planned end-of-treatment visit
F IGURE 3 Frequency and timings
of intercurrent events in the PIONEER
1 trial9
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results for both estimands are dependent on the frequency of intercur-
rent events and will be similar if these are very low. The PIONEER
1 trial had a very high completion rate (92% to 97%), and 85% to 87%
of patients across the four treatment arms completed the trial and con-
tinued with trial product without use of rescue medication,9 thus pro-
viding a high degree of concordance between the results of the two
estimands. The frequency and timing of intercurrent events during the
PIONEER 1 trial is illustrated in Figure 3.
It is of interest to note the way in which handling of intercurrent
events is reflected in the reported results. With the highest dose of
oral semaglutide tested (14 mg), the estimated treatment difference in
HbA1c, compared with placebo, as assessed by the trial product
estimand (that is, the treatment effect if rescue medication had not
been initiated and all patients remained on the trial product), was
greater by 0.3% points than the estimated treatment effect according
to the treatment policy estimand (that is, the treatment effect regard-
less of discontinuation of trial product or use of rescue medication)
(Figure 2). This was primarily the result of the greater reduction in
HbA1c with placebo for the treatment policy estimand, which is prob-
ably a reflection of the increased use of rescue medication in the pla-
cebo group (14%) vs the oral semaglutide 14 mg group (1.1%).9
Discontinuation of trial product occurred more frequently with oral
semaglutide 14 mg compared with placebo (Figure 3) and, as the
majority did not switch to another glucose-lowering agent or may
have switched to a less effective glucose-lowering agent, the inclusion
of data after trial product discontinuation for the treatment policy
estimand could also have contributed to the smaller treatment differ-
ence observed between oral semaglutide 14 mg and placebo. Like-
wise, with oral semaglutide 14 mg, the estimated treatment difference
vs placebo for body weight was greater by 0.3 kg for the trial product
estimand than for the treatment policy estimand (Figure 2), which
may be because semaglutide has been shown to markedly reduce
body weight compared with many other glucose-lowering agents22-24
and, consequently, patients who discontinued trial product prema-
turely would not be expected to experience the same weight loss as
those continuing the trial product.
6 | SUMMARY
The ICH E9 (R1) draft addendum provides a general framework to
ensure alignment of trial planning, trial design, trial conduct, data anal-
ysis and interpretation of results. Clearly defining the estimand(s) for a
trial provides greater clarity with respect to the type of treatment
effect being estimated. Defining an estimand is a multidisciplinary task
and the relevance of a specific estimand depends on the clinical set-
ting. The ICH E9 (R1) draft addendum does not recommend the use of
specific estimands, but rather, introduces the general framework and
the concept of estimands.
Including more than one estimand allows evaluation of the treat-
ment effect from different perspectives. Clinicians may find the treat-
ment effect determined by the trial product estimand to be of interest
when assessing and comparing effects of different therapeutic
choices, as this targets the expected treatment effect assuming that a
patient continues to use trial product without the need for rescue
medication. Complementing the understanding of the trial product
treatment effect is the overall effect, that is, the efficacy and tolerabil-
ity of a therapeutic choice or pathway. Hence, the treatment policy
estimand, which accounts for the addition of rescue medication, as
well as discontinuation and/or switch of medication because of tolera-
bility concerns, may provide a broader perspective concerning treat-
ment effect. The approaches are complementary in understanding the
full treatment effect of medication within different scenarios.
As seen in the PIONEER trial programme, estimands are now
being incorporated in type 2 diabetes clinical trials. Greater familiarity
with the concept of estimands and the reasons why estimands have
been introduced, along with an appreciation of the clarity provided by
use of estimands, will help clinicians who treat diabetes in interpreting
and comparing trial results and in making informed clinical decisions.
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